Trav11 (TCRAV11S1) as a Drug Target and Biomarker (G28675)

Target Name: TRAV11

NCBI ID: G28675

TRAV11

Other Name(s): TCRAV11S1 | T cell receptor alpha variable 11 (pseudogene)

Trav11 (TCRAV11S1) as a Drug Target and Biomarker

Abstract:

Trav11 (TCRAV11S1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of cell adhesion and has been shown to play a crucial role in various physiological processes, including cell migration, angiogenesis , and tissue repair. This article discusses the potential implications of Trav11 as a drug target and biomarker, as well as its current research status and potential future developments.

Introduction:

Trav11 (T cell receptor alpha-beta 11 subunit) is a non-coding RNA molecule that is expressed in various tissues and cell types, including the brain, heart, and gastrointestinal tract. It is a key regulator of cell adhesion and has been shown to play a crucial role in various physiological processes, including cell migration, angiogenesis, and tissue repair.

Recent studies have identified Trav11 as a potential drug target and biomarker, with potential therapeutic applications in a range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This article will provide an overview of Trav11's biology, potential drug target properties, and current research status, as well as discussing its potential future developments.

Trav11's Biology:

Trav11 is a non-coding RNA molecule that is expressed in various tissues and cell types, including the brain, heart, and gastrointestinal tract. It is composed of 251 amino acid residues and has a calculated molecular weight of 30 kDa. Trav11 is highly conserved across various species, with only one splice variant identified.

Trav11 has been shown to play a crucial role in various physiological processes, including cell adhesion, migration, and angiogenesis. It is a key regulator of cell-cell adhesion and has been shown to promote the formation of tight junctions, which are a type of cell-cell adhesion structure. Trav11 has also been shown to regulate the migration of various cell types, including neural cells, and to play a role in the development and progression of neurodegenerative diseases.

Potential Drug Targets:

Trav11 has been identified as a potential drug target due to its unique biology and the involvement of various diseases. Several studies have shown that Trav11 can be targeted by small molecules and antibodies, with potential therapeutic applications in a range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the potential drug targets for Trav11 is its role in cancer. Trav11 has been shown to promote the growth and survival of various cancer cell types and has been identified as a potential therapeutic target for cancer. Several studies have shown that inhibiting Trav11 can be Effective in treating various types of cancer, including breast, ovarian, and colorectal cancers.

Another potential drug target for Trav11 is its role in neurodegenerative diseases. Trav11 has been shown to contribute to the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Several studies have shown that modulating Trav11 expression can be effective in treating neurodegenerative diseases , including Alzheimer's disease.

Trav11 has also been shown to be involved in autoimmune disorders, including multiple sclerosis and rheumatoid arthritis. It has been shown to contribute to the development and progression of autoimmune disorders and has been identified as a potential therapeutic target for these disorders.

Current Research Status:

Currently, there is limited research on Trav11, and its potential drug targets and applications are still being explored. Only some research shows that Trav11 can be targeted by small molecules and antibodies, and its potential therapeutic applications in cancer, neurodegenerative diseases, and autoimmune disorders are being investigated.

future developments:

The potential of Trav11 as a drug target and biomarker is still being explored, and several studies are being conducted to determine its potential therapeutic applications. Further research is needed to understand the full biology of Trav11 and its potential as a drug target, as well as to identify and test new therapeutic applications for Trav11 in various diseases.

Conclusion:

Trav11 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of cell adhesion and has been shown to play a crucial role in various physiological processes, including cell migration, angiogenesis, and tissue repair. As a potential drug target, Trav11 has the potential to contribute to the treatment of a range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand Trav11's biology and potential therapeutic applications.

Protein Name: T Cell Receptor Alpha Variable 11 (pseudogene)

The "TRAV11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAV11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets